As of November 10, 2026, Whitehawk Therapeutics, Inc. is a publicly traded company (Nasdaq: WHWK). The largest holder reporting an active stake on Schedule 13D is Avoro Capital Advisors LLC, at 19.99%. No bankruptcy or receivership appears in its SEC Form 8-K filings. Passive holders reporting on Schedule 13G include Fan Yu (9.4%), OrbiMed (7.3%), Coastlands Capital LP (5.98%) (Schedule 13D/A, May 14, 2026).
Is this your company?
About to sign with, pay or invest in Whitehawk Therapeutics, Inc.? See the free Snapshot first.
Free to see. No signup.
Is Whitehawk Therapeutics, Inc. a real, registered company?
- Whitehawk Therapeutics, Inc. files with the SEC under CIK 1422142 (its SEC filings).
- Its shares are listed under the ticker WHWK on Nasdaq (SEC company record).
- Incorporated in Delaware; business address in Morristown, New Jersey, as its SEC filings state.
- Court and bankruptcy records: see Before you sign or pay below.
Before you sign or pay
- Court and bankruptcy: No federal court case or bankruptcy filing found under Aadi Bioscience, Inc. in our court records and SEC 8-K records (as of 2026-11-10).
- Leadership changes: the latest reported is Vijay Iyengar, Director (Form 8-K filed 2026-09-10). Check you are dealing with the people now in charge.
- Ownership: 5%+ holders are reported on Schedule 13D or 13G; the latest names OrbiMed (filed 2026-08-14).
Who are Whitehawk Therapeutics, Inc.'s owners and officers?
Whitehawk Therapeutics, Inc.: incorporated in Delaware; business address in Morristown, New Jersey; industry Pharmaceutical Preparations (Form D, 2026-09-10).
Officers and directors, each with the role and the filing that names them:
- : Executive Officer, Director (Form D, 2025-03-18)
- : Executive Officer (Form D, 2025-03-18)
- : Director (Form D, 2025-03-18)
- : Director (Form D, 2025-03-18)
- : Director (Form D, 2025-03-18)
- : Director (Form D, 2025-03-18)
- : Director (Form D, 2025-03-18)
- : Director (Form D, 2025-03-18)
- : Director (Form D, 2025-03-18)
- : Director (Form D, 2025-03-18)
- : Director (Form D, 2025-03-18)
- : Executive Officer (Form D, 2025-03-18)
| Report | Holder | Share |
|---|---|---|
| Schedule 13G/A, 2026-08-14 | Orbimed Advisors LLC | 7.3% |
| Schedule 13G/A, 2026-08-14 | Fan Yu | 9.4% |
| Schedule 13D/A, 2026-05-18 | Acuta Capital Partners, LLC | 9% |
| Schedule 13D/A, 2026-05-14 | Avoro Capital Advisors LLC | 19.99% |
| Schedule 13G, 2025-08-25 | Coastlands Capital LP | 5.98% |
Questions about who owns Whitehawk Therapeutics, Inc.
Who owns Whitehawk Therapeutics, Inc.?
On this page, 5 holders' latest ownership filings report 5% or more of Whitehawk Therapeutics, Inc.: Avoro Capital Advisors LLC (19.99%, Schedule 13D/A, filed 2026-05-14), Fan Yu (9.4%, Schedule 13G/A, filed 2026-08-14), Acuta Capital Partners, LLC (9%, Schedule 13D/A, filed 2026-05-18), Orbimed Advisors LLC (7.3%, Schedule 13G/A, filed 2026-08-14) and Coastlands Capital LP (5.98%, Schedule 13G, filed 2025-08-25).
Who are the largest shareholders of Whitehawk Therapeutics, Inc.?
By the share each holder's latest filing reports, the largest holders of Whitehawk Therapeutics, Inc. on this page are Avoro Capital Advisors LLC (19.99%), Fan Yu (9.4%) and Acuta Capital Partners, LLC (9%).
When did Avoro Capital Advisors LLC buy into Whitehawk Therapeutics, Inc.?
The filings give report dates, not purchase dates. The earliest filing from Avoro Capital Advisors LLC on this page is the Schedule 13D/A, filed 2026-05-14, reporting 19.99%. That earliest filing is itself an amendment, which updates an earlier report.
Is this an audit or a full list?
Neither. The ownership list on this page covers only Schedule 13D and 13G filings, which holders make once they own 5% or more of a class of shares (an amendment can report a stake that has since fallen below 5%); 5 such filings are shown here. It is not an audit and not a full cap table: holders who never reached 5% are not listed, and a stake can change after its latest filing.
Want the whole picture on Whitehawk Therapeutics, Inc.?
Example from a real report (our sample on Target): “In March 2026, Target announced a planned incremental $1 billion operating investment” Source: Target Corporation (press release)
A Full Report on Whitehawk Therapeutics, Inc.: verified, sourced, every claim cited, ready in a few minutes. See pricing.
What the Full Report on Whitehawk Therapeutics, Inc. covers
The Short Answer
Which Company This Is
What They Do, And How The Money Works
Who Runs It, And How To Reach Them
The Money: Funding, Valuation, Runway
Who Pays Them, And Who They Are Up Against
Warning Bells
Sources
14 cited sources found
Plus the sections for what you are deciding, which you pick after ordering.
A real finished report, first screen. Opens in a new tab.
| Filed | Person | Role | Change | Effective |
|---|---|---|---|---|
| Form 8-K, 2026-09-10 | Vijay Iyengar | Director | appointed | 2026-09-09 |
Which insiders own Whitehawk Therapeutics, Inc. shares?
Directors, officers and holders of 10% or more report their shares on Forms 3, 4 and 5. Each line is the latest such report, largest holding first.
- , a director: 4,687,042 shares (7.9% of shares outstanding), 1,130 held directly and 4,685,912 indirectly (Form 4, 2026-07-30).
- , a director: 2,440,794 shares (4.1% of shares outstanding), 274,796 held directly and 2,165,998 indirectly (Form 4, 2026-05-18).
- , a director: 1,250,000 shares (2.1% of shares outstanding), held indirectly (the form names the holder only in its footnotes) (Form 4, 2025-03-04).
- , the chief executive and a director: 569,643 shares (0.97% of shares outstanding) (Form 4, 2026-05-18).
- Bryan Ball: 448,126 shares (0.76% of shares outstanding) (Form 4, 2026-05-18).
Shares outstanding: 59,008,982 as of 2026-11-05, from the company's latest SEC cover page.
How much has Whitehawk Therapeutics, Inc. raised?
| Filed | Sold | Offered |
|---|---|---|
| Form D, 2025-03-18 | $100M | $100M |
| Form D, 2022-10-11 | $72.50M | $72.50M |
Keep reading
More on Whitehawk Therapeutics, Inc. and the records around it.
Whitehawk Therapeutics, Inc. elsewhere on the record
- Leadership changes Sep 2026
- 5%+ stake filings Aug 2026
- Form D filing Mar 2025
Companies that share a holder
- ABG Management Ltd. also filed stake reports on 2 other companies: ProMIS Neurosciences Inc. (Feb 2026), Ceribell, Inc. (Dec 2025)
- Coastlands Capital LP also filed stake reports on 16 other companies: Sutro Biopharma, Inc. (Nov 2026), Bolt Biotherapeutics, Inc. (Nov 2026), Kalaris Therapeutics, Inc. (Oct 2026)
- Avoro Capital Advisors LLC also filed stake reports on 18 other companies: Arrowhead Pharmaceuticals, Inc. (Aug 2026), Avalo Therapeutics, Inc. (Aug 2026), Hemab Therapeutics Holdings, Inc. (Aug 2026)
Related pages
Filings, cases and notices link to their records. A not-found line names the records searched; it is not proof of absence.
Not for employment, credit, insurance or tenancy decisions.
Cite this page
https://mentionfox.com/who-owns/whitehawk-therapeutics